Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors

Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board
of Directors

BOTHELL, Wash., Nov. 5 /PRNewswire-FirstCall/ -- Cardiac Science Corporation
(Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and
diagnostic cardiac monitoring devices, announced today it appointed veteran
healthcare executive Ronald A. Andrews, Jr., to its board of directors.
Andrews replaces long-time board member Jue-Hsien Chern, Ph.D., who stepped
down from his board seat effective November 5th. The total number of directors
remains at six.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

Andrews, 50, is the vice chairman and chief executive officer of Clarient,
Inc. (Nasdaq: CLRT), an advanced cancer diagnostics and laboratory services
company serving pathologists, oncologists, and the pharmaceutical industry.
Andrews joined Clarient in July 2004 and implemented a completely new business
model for the company that generated annual revenue growth from nominal levels
to a run rate approaching $100 million.

"Ronnie is a natural leader and innovator with a proven ability to manage
growth," said Board Chairman Ruediger Naumann-Etienne, Ph.D. "His experience
in global marketing and business development, especially when it comes to
combining technology and service offerings, will be valuable to Cardiac
Science as we execute our growth strategy. We look forward to working with
Ronnie and welcome the expertise and enthusiasm we know he will bring to our
board."

Prior to joining Clarient, Andrews was senior vice president global marketing
and commercial business development at Pleasanton, CA-based Roche Molecular
Diagnostics, where he was responsible for all aspects of strategy and
commercial operations. From 2000 to 2002, Andrews held two senior executive
positions with Indianapolis-based Roche Diagnostics Corporation: vice
president, U.S. commercial operations, molecular diagnostics, and vice
president, marketing, U.S. commercial operations.

Andrews earned a bachelor's degree in biology and chemistry from Wofford
College and has participated extensively in the executive development programs
at Roche and Abbott Labs.

About Cardiac Science:

Cardiac Science develops, manufactures, and markets a family of advanced
diagnostic and therapeutic cardiology devices and systems, including automated
external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac
stress treadmill and systems, Holter monitoring systems, hospital
defibrillators, cardiac rehabilitation telemetry systems, vital signs
monitors, and cardiology data management systems (informatics) that connect
with hospital information (HIS), electronic medical record (EMR), and other
information systems. The company sells a variety of related products and
consumables and provides a portfolio of training, maintenance, and support
services. Cardiac Science, the successor to the cardiac businesses that
established the trusted Burdick®, HeartCentrix®, Powerheart®, and Quinton®
brands, is headquartered in Bothell, Washington. With customers in more than
100 countries worldwide, the company has operations in North America, Europe,
and Asia. For information, call 425.402.2000 or visit
http://www.cardiacscience.com.

For updates and information on worldwide defibrillation and cardiac
monitoring, find us on the Cardiac Science blog at
http://www.cardiacscience.com/blog, Twitter at
http://twitter.com/cardiacscience, Facebook at http://budurl.com/CSonFB,
YouTube at http://www.youtube.com/user/CardiacScience.

Forward-Looking Statements

This press release contains forward-looking statements. The words "believe,"
"expect," "intend," "anticipate," variations of such words, and similar
expressions identify forward-looking statements, but their absence does not
mean that the statement is not forward-looking. Forward-looking statements in
this press release include, but are not limited to, those relating to Cardiac
Science Corporation's growth strategies and the resulting impact on operating
results. These are forward-looking statements for purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of 1995. Actual
results may vary significantly from the results expressed or implied in such
statements. Factors that could cause or contribute to such varying results and
other risks are more fully described in Cardiac Science Corporation's Annual
Report on Form 10-K for the year ended December 31, 2008, as updated by
subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation
undertakes no duty or obligation to update the information provided herein.

LOGO: http://www.cardiacscience.com/images/main_logo.gif
CSCX-F

Company Contact: Investor Contact:
Mike Matysik Matt Clawson
Cardiac Science Corporation Allen & Caron
Senior Vice President and CFO 949.474.4300
425.402.2009 matt@allencaron.com

Media Contact:
Christopher Gale
EVC Group Inc.
646.201.5431
203.570.4681
cgale@evcgroup.com

SOURCE Cardiac Science Corporation

Company Contact, Mike Matysik, Senior Vice President and CFO of Cardiac
Science Corporation, +1-425-402-2009; or Investors, Matt Clawson of Allen &
Caron, +1-949-474-4300, matt@allencaron.com; or Media, Christopher Gale of EVC
Group Inc., +1-646-201-5431, or +1-203-570-4681, cgale@evcgroup.com, both for
Cardiac Science Corporation